BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 19332043)

  • 1. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
    Tsai SM; Lin CY; Wu SH; Hou LA; Ma H; Tsai LY; Hou MF
    Clin Chim Acta; 2009 Jun; 404(2):160-5. PubMed ID: 19332043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
    Chew SC; Singh O; Chen X; Ramasamy RD; Kulkarni T; Lee EJ; Tan EH; Lim WT; Chowbay B
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1471-8. PubMed ID: 21468756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
    Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
    Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?
    Magliulo L; Dahl ML; Lombardi G; Fallarini S; Villa LM; Biolcati A; Scordo MG
    Eur J Clin Pharmacol; 2011 Jan; 67(1):47-54. PubMed ID: 20931330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.
    Kim KP; Ahn JH; Kim SB; Jung KH; Yoon DH; Lee JS; Ahn SH
    Cancer Chemother Pharmacol; 2012 May; 69(5):1221-7. PubMed ID: 22271208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
    Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
    Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation.
    Bouamar R; Hesselink DA; van Schaik RH; Weimar W; Macphee IA; de Fijter JW; van Gelder T
    Ther Drug Monit; 2011 Apr; 33(2):178-84. PubMed ID: 21383650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.
    Provenzani A; Notarbartolo M; Labbozzetta M; Poma P; Vizzini G; Salis P; Caccamo C; Bertani T; Palazzo U; Polidori P; Gridelli B; D'Alessandro N
    Int J Mol Med; 2011 Dec; 28(6):1093-102. PubMed ID: 21922127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients.
    Provenzani A; Notarbartolo M; Labbozzetta M; Poma P; Biondi F; Sanguedolce R; Vizzini G; Palazzo U; Polidori P; Triolo F; Gridelli B; D'Alessandro N
    Ann Transplant; 2009; 14(1):23-31. PubMed ID: 19289993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer.
    Ozeki T; Nagahama M; Fujita K; Suzuki A; Sugino K; Ito K; Miura M
    Sci Rep; 2019 Apr; 9(1):5404. PubMed ID: 30931962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Allelic Interaction of Single Nucleotide Polymorphisms of Influx and Efflux Transporters Genes With Nonhematologic Adverse Events of Docetaxel in Breast Cancer Patients.
    Jabir RS; Ho GF; Annuar MABA; Stanslas J
    Clin Breast Cancer; 2018 Oct; 18(5):e1173-e1179. PubMed ID: 29885788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
    Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
    Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients.
    Genvigir FD; Salgado PC; Felipe CR; Luo EY; Alves C; Cerda A; Tedesco-Silva H; Medina-Pestana JO; Oliveira N; Rodrigues AC; Doi SQ; Hirata MH; Hirata RD
    Pharmacogenet Genomics; 2016 Oct; 26(10):462-72. PubMed ID: 27434656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.
    Angelini S; Botticelli A; Onesti CE; Giusti R; Sini V; Durante V; Strigari L; Gentile G; Cerbelli B; Pellegrini P; Sgroi V; Occhipinti M; DI Pietro FR; Rossi A; Simmaco M; Mazzuca F; Marchetti P
    Anticancer Res; 2017 May; 37(5):2633-2639. PubMed ID: 28476838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients.
    Qiu F; He XJ; Sun YX; Li-Ling J; Zhao LM
    Pharmacol Rep; 2011; 63(3):815-25. PubMed ID: 21857093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
    Sissung TM; Baum CE; Deeken J; Price DK; Aragon-Ching J; Steinberg SM; Dahut W; Sparreboom A; Figg WD
    Clin Cancer Res; 2008 Jul; 14(14):4543-9. PubMed ID: 18628469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms.
    Tran A; Jullien V; Alexandre J; Rey E; Rabillon F; Girre V; Dieras V; Pons G; Goldwasser F; Tréluyer JM
    Clin Pharmacol Ther; 2006 Jun; 79(6):570-80. PubMed ID: 16765145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation.
    Turolo S; Tirelli AS; Ferraresso M; Ghio L; Belingheri M; Groppali E; Torresani E; Edefonti A
    Pharmacol Rep; 2010; 62(6):1159-69. PubMed ID: 21273673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.